CJC-1295
Prescription OnlyOverview
CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analogue. It is one of the most commonly prescribed peptides in Australia, frequently used in combination with Ipamorelin. The regulatory environment is stable with no anticipated changes.
Australian Scheduling
Schedule 4 (Prescription Only). Stable classification with no signalled changes from the TGA. Available through standard compounding pharmacy pathways.
Access Pathway
Widely available through telehealth peptide clinics and compounding pharmacies nationally. Commonly prescribed as a CJC-1295/Ipamorelin combination. 15 identified Australian providers.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.